As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Autolus Therapeutics plc. The largest reported stake is MAK Capital Fund LP's, at 12.6%. 10 filings are on record since October 6, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like Autolus Therapeutics plc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Renata Kellnerova · Sole voting: 0 · Shared voting: 14,782,275 · Sole dispositive: 0 · Shared dispositive: 14,782,275 · SCHEDULE 13D/A, 2026-08-28
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 15,000,000 · Sole dispositive: 0 · Shared dispositive: 15,000,000 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Armistice Capital, LLC · Percent: 5.94% · SCHEDULE 13G/A
- · Holder: MAK Capital Fund LP · Percent: 12.6% · SCHEDULE 13G/A
- · Holder: Armistice Capital, LLC · Percent: 6.58% · SCHEDULE 13G/A
Autolus Therapeutics plc has 10 Schedule 13D or 13G filings on record since 2025-10-06. 3 holders' latest filing reports 5% or more of adss, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $0.000042 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-04-29 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| MAK Capital Fund LP | 12.6% | 33,621,487 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Armistice Capital, LLC | 5.64% | 15,000,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| PPF Group a.s. | 5.6% | 14,782,275 | SCHEDULE 13D/A, 2026-08-28 | 2026-08-27 |
| Deep Track Capital, LP | 0.97% | 2,568,613 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Wellington Management Group LLP | 0% | 0 | SCHEDULE 13G/A, 2025-10-06 | 2025-09-30 |
Holding shares or following this stake? See who's behind Autolus Therapeutics plc and the warning signs.
Free to see. No signup.
Keep reading
More on Autolus Therapeutics plc and the records around it.
Autolus Therapeutics plc elsewhere on the record
- Layoff notices Apr 2026
- Who owns it
Companies that share a holder
- Renata Kellnerova also filed stake reports on 2 other companies: MARINEMAX INC (Sep 2026), MDA Space Ltd. (May 2026)
- MAK Capital Fund LP also filed stake reports on 7 other companies: Comstock Inc. (Oct 2026), ClearPoint Neuro, Inc. (May 2026), STANDARD BIOTOOLS INC. (May 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Autolus Therapeutics plc
Get an email when Autolus Therapeutics plc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Autolus Therapeutics plc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Autolus Therapeutics plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Autolus Therapeutics plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 0 | 15,000,000 | 0 | 15,000,000 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 15,000,000 | 0 | 15,000,000 | SCHEDULE 13G/A, 2026-08-14 |
| Renata Kellnerova | 0 | 14,782,275 | 0 | 14,782,275 | SCHEDULE 13D/A, 2026-08-28 |
| AMALAR HOLDING s.r.o. | 0 | 14,782,275 | 0 | 14,782,275 | SCHEDULE 13D/A, 2026-08-28 |
| PPF Group a.s. | 0 | 14,782,275 | 0 | 14,782,275 | SCHEDULE 13D/A, 2026-08-28 |
| PPF IM Ltd. | 0 | 14,782,275 | 0 | 14,782,275 | SCHEDULE 13D/A, 2026-08-28 |
The latest filing identifies Autolus Therapeutics plc by CUSIP 05280R100 and gives its principal executive office as The Mediaworks, 191 Wood Lane, London (SCHEDULE 13D/A, 2026-08-28).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and supplemented to include the following: The Ordinary Shares reported herein were transferred by PPF Biotech B.V. to PPF IM by way of an intercompany transfer among affiliated entities under common ultimate ownership and control as part of an internal reorganization of the PPF group of companies. The internal reorganization was completed on August 27, 2026.PPF Group a.s., SCHEDULE 13D/A, 2026-08-28
Purpose of Transaction (Item 4)
PPF Group a.s.
Item 4 of the Schedule 13D is hereby amended and supplemented to include the following: The transactions described in this Amendment No. 11 were undertaken solely to effect an internal reorganization of the PPF group of companies. Such transactions did not involve any change in the ultimate beneficial ownership of, or the ultimate voting or dispositive power over, the Ordinary Shares reported herein, and were not undertaken with any purpose of, or with the effect of, changing or influencing control of the Issuer. Other than as described herein, the Reporting Persons do not have any current plans or proposals which relate to or would result in any of the actions described in subparagraphs (a) through (j) above.Item 4 of the SCHEDULE 13D/A filed 2026-08-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-06 | Wellington Management Group LLP | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Deep Track Capital, LP | 0.97% | SCHEDULE 13G/A |
| 2025-11-14 | Armistice Capital, LLC | 5.86% | SCHEDULE 13G |
| 2025-12-03 | MAK Capital Fund LP | 10.1% | SCHEDULE 13G/A |
| 2026-02-13 | MAK Capital Fund LP | 11.3% | SCHEDULE 13G/A |
| 2026-02-17 | Armistice Capital, LLC | 6.58% | SCHEDULE 13G/A |
| 2026-05-15 | Armistice Capital, LLC | 5.94% | SCHEDULE 13G/A |
| 2026-05-15 | MAK Capital Fund LP | 12.6% | SCHEDULE 13G/A |
| 2026-08-14 | Armistice Capital, LLC | 5.64% | SCHEDULE 13G/A |
| 2026-08-28 | PPF Group a.s. | 5.6% | SCHEDULE 13D/A |
Questions about who owns Autolus Therapeutics plc
Who owns Autolus Therapeutics plc?
On this page, 3 holders' latest ownership filings report 5% or more of Autolus Therapeutics plc: MAK Capital Fund LP (12.6%, Schedule 13G/A, filed 2026-05-15), Armistice Capital, LLC (5.64%, Schedule 13G/A, filed 2026-08-14) and PPF Group a.s. (5.6%, Schedule 13D/A, filed 2026-08-28).
Who are the largest shareholders of Autolus Therapeutics plc?
By the share each holder's latest filing reports, the largest holders of Autolus Therapeutics plc on this page are MAK Capital Fund LP (12.6%), Armistice Capital, LLC (5.64%) and PPF Group a.s. (5.6%).
When did MAK Capital Fund LP buy into Autolus Therapeutics plc?
The filings give report dates, not purchase dates. The earliest filing from MAK Capital Fund LP on this page is the Schedule 13G/A, filed 2025-12-03, reporting 10.1%; its latest, Schedule 13G/A filed 2026-05-15, reports 12.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Autolus Therapeutics plc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.